Stemline Therapeutics Inc. (STML) Shares Down 1.7%
Stemline Therapeutics Inc. (NASDAQ:STML) traded down 1.7% during mid-day trading on Tuesday . The stock traded as low as $8.46 and last traded at $8.55, with a volume of 91,042 shares changing hands. The stock had previously closed at $8.70.
Several equities research analysts have issued reports on the stock. Jefferies Group reissued a “buy” rating and issued a $23.00 price objective on shares of Stemline Therapeutics in a research report on Monday, June 6th. Zacks Investment Research raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research report on Wednesday, July 6th. Wedbush reissued an “outperform” rating and issued a $16.00 price objective on shares of Stemline Therapeutics in a research report on Tuesday, June 7th. Finally, Roth Capital reissued a “buy” rating and issued a $32.00 price objective on shares of Stemline Therapeutics in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $19.31.
The firm has a 50 day moving average of $7.49 and a 200 day moving average of $6.28. The firm’s market capitalization is $151.16 million.
Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Equities analysts expect that Stemline Therapeutics Inc. will post ($2.11) earnings per share for the current fiscal year.
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.